ContractInterleukin Genetics Inc • April 17th, 2017 • In vitro & in vivo diagnostic substances • Delaware
THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (iv) OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THIS WARRANT.
SECOND amendment of VENTURE LOAN AND SECURITY AGREEMENTVenture Loan and Security Agreement • April 17th, 2017 • Interleukin Genetics Inc • In vitro & in vivo diagnostic substances • Connecticut
This SECOND AMENDMENT OF VENTURE LOAN AND SECURITY AGREEMENT (this “Agreement”), dated as of April 17, 2017, is entered into by and among INTERLEUKIN GENETICS, INC. (“Borrower”) and HORIZON CREDIT II LLC, as assignee of Horizon Technology Finance Corporation (“Lender”).
SUBSCRIPTION AGREEMENTSubscription Agreement • April 17th, 2017 • Interleukin Genetics Inc • In vitro & in vivo diagnostic substances • Massachusetts
Subject to the terms and conditions set forth in this Subscription Agreement, dated as of April 17, 2017 (this “Agreement”), each of the undersigned (each, a “Subscriber” and collectively, the “Subscribers”) hereby offers to purchase from Interleukin Genetics, a Delaware corporation (the “Company”), a subordinated convertible promissory note in an original principal amount equal to the “Note Principal Amount” set forth with its signature on the signature page hereto, the form of which is attached as Exhibit A hereto, (the “Note” and, collectively, the “Notes”) and a warrant, substantially in the form of Exhibit B hereto (the “Warrant” and, collectively, the “Warrants”), representing the right to purchase shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), exercisable as set forth therein. The Note is convertible into shares of Common Stock (the “Conversion Shares,” and together with the Notes, the Warrants and the Warrant Shares (as defined below), the “S
